Herpesviridae Infections is an indication for drug development with over 310 pipeline drugs currently active. According to GlobalData, preregistered drugs for Herpesviridae Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Herpesviridae Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Herpesviridae Infections overview

The infections caused by Herpesviridae viruses are called Herpesviridae Infections. These viruses are characterized by their ability to establish latent infections, they can remain dormant in the body and reactivate later. Herpesviruses are highly contagious and are typically transmitted through direct contact with infected individuals or their bodily fluids. While some infections may cause mild symptoms, others can lead to more severe conditions, especially in individuals with compromised immune systems.

For a complete picture of PTSR and LoA scores for drugs in Herpesviridae Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.